JP2019514877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514877A5 JP2019514877A5 JP2018555177A JP2018555177A JP2019514877A5 JP 2019514877 A5 JP2019514877 A5 JP 2019514877A5 JP 2018555177 A JP2018555177 A JP 2018555177A JP 2018555177 A JP2018555177 A JP 2018555177A JP 2019514877 A5 JP2019514877 A5 JP 2019514877A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- linker
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 4
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 235000013877 carbamide Nutrition 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 150000003457 sulfones Chemical class 0.000 claims description 4
- 150000003568 thioethers Chemical class 0.000 claims description 4
- 102000015367 CRBN Human genes 0.000 claims description 2
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims description 2
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims description 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims description 2
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 2
- 230000018883 protein targeting Effects 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 0 *Nc(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound *Nc(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O 0.000 description 2
- BTODVRFBCGOZGM-UHFFFAOYSA-N CC(C)Nc(cccc1C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound CC(C)Nc(cccc1C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O BTODVRFBCGOZGM-UHFFFAOYSA-N 0.000 description 1
- AOAWMQJVACPFTA-UHFFFAOYSA-N CC(C)Nc(cccc1CN2C(CCC(N3)=O)C3=O)c1C2=O Chemical compound CC(C)Nc(cccc1CN2C(CCC(N3)=O)C3=O)c1C2=O AOAWMQJVACPFTA-UHFFFAOYSA-N 0.000 description 1
- KBKBMAPKDBDLGN-UHFFFAOYSA-N CC(C)Oc(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound CC(C)Oc(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O KBKBMAPKDBDLGN-UHFFFAOYSA-N 0.000 description 1
- SBEBGZQERFEASE-UHFFFAOYSA-N CCC(C)c(cc1C(N2C(CCC(N3)=O)C3=O)=O)ccc1C2=O Chemical compound CCC(C)c(cc1C(N2C(CCC(N3)=O)C3=O)=O)ccc1C2=O SBEBGZQERFEASE-UHFFFAOYSA-N 0.000 description 1
- FAZWECWNUTULOK-UHFFFAOYSA-N CCc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound CCc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O FAZWECWNUTULOK-UHFFFAOYSA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O Chemical compound Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325856P | 2016-04-21 | 2016-04-21 | |
| US62/325,856 | 2016-04-21 | ||
| PCT/US2017/028875 WO2017184995A1 (en) | 2016-04-21 | 2017-04-21 | Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514877A JP2019514877A (ja) | 2019-06-06 |
| JP2019514877A5 true JP2019514877A5 (enExample) | 2020-06-11 |
| JP6936498B2 JP6936498B2 (ja) | 2021-09-15 |
Family
ID=60116391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555177A Active JP6936498B2 (ja) | 2016-04-21 | 2017-04-21 | 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10807977B2 (enExample) |
| EP (1) | EP3445452A4 (enExample) |
| JP (1) | JP6936498B2 (enExample) |
| KR (1) | KR102447884B1 (enExample) |
| CN (1) | CN109152933B (enExample) |
| AU (1) | AU2017254687B2 (enExample) |
| CA (1) | CA3018991A1 (enExample) |
| WO (2) | WO2017184995A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11331328B2 (en) | 2014-05-05 | 2022-05-17 | Bioventures, Llc | Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents |
| CA2955972A1 (en) | 2014-07-22 | 2016-01-28 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| AU2017341723B2 (en) | 2016-10-11 | 2021-12-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| EP3535265A4 (en) | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE |
| KR102656934B1 (ko) | 2017-07-10 | 2024-04-16 | 셀진 코포레이션 | 항증식성 화합물 및 이의 사용 방법 |
| ES3013457T3 (en) | 2018-01-10 | 2025-04-14 | Recurium Ip Holdings Llc | Benzamide compounds as bci inhibitors for the treatment of hiv |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| US12084423B2 (en) | 2018-05-18 | 2024-09-10 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| WO2019218904A1 (zh) * | 2018-05-18 | 2019-11-21 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、其制备方法及用途 |
| US11026963B2 (en) * | 2018-07-11 | 2021-06-08 | Rubedo Life Sciences, Inc. | Senolytic compositions and uses thereof |
| US20220169628A1 (en) * | 2019-02-08 | 2022-06-02 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| MX2022000310A (es) * | 2019-07-10 | 2022-02-10 | Recurium Ip Holdings Llc | Inhibidores de proteina bcl-2. |
| CN114867727B (zh) * | 2019-07-17 | 2025-02-21 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| JP7502425B2 (ja) * | 2019-10-01 | 2024-06-18 | アルヴィナス・オペレーションズ・インコーポレイテッド | Ｂｒｍ標的化化合物および関連使用方法 |
| WO2021078301A1 (zh) * | 2019-10-24 | 2021-04-29 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| CN115038448B (zh) * | 2019-12-17 | 2024-09-10 | 奥里尼斯生物科学股份有限公司 | 调节蛋白质募集和/或降解的化合物 |
| JP2023510885A (ja) * | 2020-01-15 | 2023-03-15 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | 治療用物質および処置方法 |
| WO2021180040A1 (zh) * | 2020-03-12 | 2021-09-16 | 南京明德新药研发有限公司 | 苯并五元环类化合物 |
| WO2021222114A1 (en) * | 2020-04-28 | 2021-11-04 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| PE20231204A1 (es) | 2020-05-09 | 2023-08-17 | Arvinas Operations Inc | Metodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificacion que comprenden el mismo |
| MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
| CN117794929A (zh) | 2021-02-02 | 2024-03-29 | 法国施维雅药厂 | 选择性bcl-xl protac化合物及使用方法 |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| WO2022255888A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| KR20240055751A (ko) * | 2021-09-01 | 2024-04-29 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | Bcl-2 패밀리 단백질을 분해하는 화합물 및 이의 의약에서의 응용 |
| US20250197387A1 (en) * | 2021-09-17 | 2025-06-19 | Kymera Therapeutics, Inc. | Bcl-xl degraders and uses thereof |
| TW202320769A (zh) * | 2021-11-17 | 2023-06-01 | 大陸商成都先導藥物開發股份有限公司 | 一種降解劑及其用途 |
| US20250154146A1 (en) * | 2022-01-04 | 2025-05-15 | Shanghaitech University | Protein degraders developed on basis of bcl-2 family protein ligand compounds and use thereof |
| WO2023205802A2 (en) * | 2022-04-22 | 2023-10-26 | Sens Research Foundation | Senolytic targets of senescent cells |
| JP2025516358A (ja) | 2022-05-06 | 2025-05-27 | ツリーライン バイオサイエンシズ インコーポレイテッド | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 |
| US20250288683A1 (en) | 2022-05-06 | 2025-09-18 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| WO2023215482A1 (en) | 2022-05-06 | 2023-11-09 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| WO2024012449A1 (zh) * | 2022-07-12 | 2024-01-18 | 正大天晴药业集团股份有限公司 | 含有三氟甲基基团的化合物 |
| EP4565236A1 (en) * | 2022-08-02 | 2025-06-11 | Beijing Neox Biotech Limited | Bcl-xl degrading compounds |
| CN115141198A (zh) * | 2022-09-01 | 2022-10-04 | 上海睿跃生物科技有限公司 | 降解蛋白的化合物及其应用和药物 |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| CN115286689B (zh) * | 2022-09-29 | 2023-01-06 | 上海睿跃生物科技有限公司 | 靶向降解Bcl-2蛋白的化合物及其应用和药物 |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
| WO2024067818A1 (zh) * | 2022-09-30 | 2024-04-04 | 江苏恒瑞医药股份有限公司 | 一种用于bcl-2蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 |
| CN115286630B (zh) * | 2022-10-09 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌嗪类化合物及其制备方法和应用 |
| WO2024078581A1 (en) * | 2022-10-12 | 2024-04-18 | Appicine Therapeutics (Hk) Limited | Selective bcl-xl protac compounds and uses thereof |
| WO2024123195A1 (en) * | 2022-12-06 | 2024-06-13 | Captor Therapeutics S.A. | Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| AU2023389065A1 (en) * | 2022-12-06 | 2025-06-19 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| WO2024169976A1 (zh) * | 2023-02-17 | 2024-08-22 | 正大天晴药业集团股份有限公司 | 含有三氟甲磺酰基的化合物 |
| WO2024245312A1 (en) * | 2023-05-30 | 2024-12-05 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
| WO2025101588A1 (en) | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| TW202535872A (zh) | 2023-11-07 | 2025-09-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| WO2025101575A1 (en) | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| WO2025117556A1 (en) * | 2023-11-27 | 2025-06-05 | Rubedo Life Sciences, Inc. | Phosphorous containing bcl inhibitors and senolytic compounds and uses thereof |
| WO2025122895A1 (en) | 2023-12-08 | 2025-06-12 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| WO2025136208A1 (en) | 2023-12-21 | 2025-06-26 | Hadjab Saida | Senolytic compounds for use in the treatment and/or prevention of a headache disorder and/or chronic pain |
| CN117624134B (zh) * | 2024-01-26 | 2024-05-03 | 南昌市第一医院 | 一种靶向降解hdac4的化合物及其制备方法和应用 |
| CN118908940B (zh) * | 2024-10-11 | 2024-12-31 | 齐鲁理工学院 | 一种靶向抗凋亡Bcl-2的蛋白水解靶向嵌合体的制备和应用 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4529561A (en) | 1978-03-24 | 1985-07-16 | The Regents Of The University Of California | Method for producing liposomes in selected size range |
| US4241046A (en) | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4925661A (en) | 1984-04-19 | 1990-05-15 | Leaf Huang | Target-specific cytotoxic liposomes |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US4755388A (en) | 1984-11-09 | 1988-07-05 | The Regents Of The University Of California | Liposome-encapsulated 5-fluoropyrimidines and methods for their use |
| DE3542773A1 (de) | 1985-12-04 | 1987-06-11 | Roehm Pharma Gmbh | Hautwirksame pharmaka mit liposomen als wirkstofftraeger |
| US4828837A (en) | 1987-03-30 | 1989-05-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition, its production and application |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5043164A (en) | 1989-01-17 | 1991-08-27 | The University Of Tennessee Research Corporation | Blood-stable, cholesterol-free liposomes |
| US5064655A (en) | 1989-02-24 | 1991-11-12 | Liposome Technology, Inc. | Liposome gel composition and method |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| JP3150695B2 (ja) | 1991-04-05 | 2001-03-26 | 鐘淵化学工業株式会社 | フェノキシベンゼン誘導体 |
| US5491069A (en) | 1994-02-18 | 1996-02-13 | The Regents Of The University Of California | Biomarkers of cell senescence |
| US5888764A (en) | 1995-01-20 | 1999-03-30 | Uab Research Foundation | Human fas gene promoter region |
| DE19713393C2 (de) | 1997-04-01 | 2002-12-05 | Apotech Res & Dev Ltd | Flip-Gen und Flip-Protein |
| JPH11349568A (ja) | 1998-06-08 | 1999-12-21 | Maruho Co Ltd | ラクタム誘導体及びその医薬用途 |
| WO2000004901A1 (en) | 1998-07-21 | 2000-02-03 | Thomas Jefferson University | Small molecule inhibitors of bcl-2 proteins |
| AUPR038200A0 (en) | 2000-09-26 | 2000-10-19 | Beta Peptide Foundation Pty Ltd, The | Compositions and methods for delaying, preventing, rejuvenating or reversing senescence |
| NZ529792A (en) | 2001-05-30 | 2007-04-27 | Univ Michigan | Small molecule antagonists of Bcl-2 family proteins |
| ES2276895T3 (es) | 2002-05-07 | 2007-07-01 | Institut Pasteur | Cribado de peptidos qque inhiben la union de pp1c a las proteinas bcl-2, bcl-xi y bcl-w. |
| WO2004066915A2 (en) | 2003-01-23 | 2004-08-12 | The Trustees Of Columbia University In The City Of New York | Old-35, a gene associated with senescence and terminal cell differentiation, and uses thereof |
| US7425553B2 (en) | 2003-05-30 | 2008-09-16 | Gemin X Pharmaceuticals Canada Inc. | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| EP1692486B1 (en) | 2003-12-12 | 2015-10-28 | Saint Louis University | Biosensors for detecting macromolecules and other analytes |
| BRPI0511504A (pt) | 2004-05-26 | 2008-01-22 | Eisai R&D Man Co Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides |
| US8557812B2 (en) | 2004-08-20 | 2013-10-15 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
| TWI337182B (en) | 2005-05-12 | 2011-02-11 | Abbott Lab | Apoptosis promoters |
| WO2008112195A1 (en) | 2007-03-09 | 2008-09-18 | Bioseek, Inc. | Methods for identifying agents and their use for the prevention or stabilization of fibrosis |
| KR20090122403A (ko) | 2007-03-29 | 2009-11-27 | 노파르티스 아게 | 증식성 질환의 치료를 위한 3-이미다졸릴-인돌 |
| WO2009042798A1 (en) | 2007-09-26 | 2009-04-02 | Cold Spring Harbor Laboratory | Methods for treating fibrosis by modulating cellular senescence |
| WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
| EP2276487A1 (en) | 2008-03-11 | 2011-01-26 | The General Hospital Corporation | Piperlongumine and piperlongumine analogs for use in the treatment of cancer |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| US20100086941A1 (en) | 2008-10-01 | 2010-04-08 | Adami Guy R | Methods for determining aged based accumulation of senescent cells using senescence specific DNA damage markers |
| PE20120305A1 (es) | 2008-12-19 | 2012-04-09 | Abbott Lab | Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl |
| SG172259A1 (en) | 2008-12-19 | 2011-07-28 | Genentech Inc | Heterocyclic compounds and methods of use |
| EP2418942B1 (en) | 2009-04-15 | 2017-08-23 | Sanford-Burnham Medical Research Institute | Naphthalene-based inhibitors of anti-apoptotic proteins |
| PE20120345A1 (es) * | 2009-05-26 | 2012-05-17 | Abbvie Bahamas Ltd | Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas |
| EP2289528A1 (en) | 2009-07-21 | 2011-03-02 | DSM IP Assets B.V. | Novel nutraceutical compositions containing black pepper or its constituents improving mental performance |
| US8349832B2 (en) | 2009-09-02 | 2013-01-08 | Canthera Therapeutics | Compounds and compositions for treating cancer |
| US8318737B2 (en) | 2009-09-02 | 2012-11-27 | Canthera Therapeutics Inc. | Compounds and compositions for treating cancer |
| US20120157455A1 (en) | 2009-09-02 | 2012-06-21 | Canthera Therapeutics, Inc. | Compounds And Compositions For Treating Cancer |
| EP2519260A2 (en) | 2009-12-31 | 2012-11-07 | Deutsches Krebsforschungszentrum | Novel modulators of trail signalling |
| CN101774875A (zh) | 2010-01-08 | 2010-07-14 | 北京欧凯纳斯科技有限公司 | 一种荜拔酰胺类化合物的合成方法 |
| CN102125552A (zh) | 2010-01-20 | 2011-07-20 | 李绍路 | 荜茇酰胺衍生物在制备治疗癌症的药物中的用途及其药物组合物 |
| CN102146054A (zh) | 2010-02-10 | 2011-08-10 | 新昌县来益科技开发有限公司 | 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途 |
| WO2011130395A1 (en) | 2010-04-13 | 2011-10-20 | University Of Utah Research Foundation | Inhibitors of flip to treat cancer |
| US20120129853A1 (en) * | 2010-11-23 | 2012-05-24 | Abbott Laboratories | Methods of treatment using selective bcl-2 inhibitors |
| US8691184B2 (en) * | 2011-01-25 | 2014-04-08 | The Regents Of The University Of Michigan | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same |
| US8940737B2 (en) | 2011-10-14 | 2015-01-27 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP2602330A1 (en) | 2011-12-07 | 2013-06-12 | Palacky University, Olomouc | Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance |
| WO2013106643A2 (en) * | 2012-01-12 | 2013-07-18 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| JP6138928B2 (ja) | 2012-06-01 | 2017-05-31 | ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー．ファウ．（エフエルイー） | 医薬に使用されるｎｏｔｃｈシグナル伝達経路及び分泌の阻害物質 |
| US9108923B2 (en) | 2012-07-20 | 2015-08-18 | Howard Hughes Medical Institute | Compounds, compositions, and methods for cancer therapy |
| CN103601670B (zh) | 2012-11-20 | 2016-06-15 | 中国人民解放军第二军医大学 | 荜拔酰胺类似物及其制备方法与应用 |
| US10279018B2 (en) | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| GB201311910D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
| HK1219734A1 (zh) * | 2013-01-16 | 2017-04-13 | The Regents Of The University Of Michigan | Bcl-2/bcl-xl抑制劑和使用所述抑制劑的治療方法 |
| MX2015014582A (es) | 2013-04-21 | 2016-07-15 | Yeda Res & Dev | Agentes para regulacion hacia abajo de la actividad y/o cantidad de bcl-xl y/o bcl-w. |
| CN110623956A (zh) * | 2014-01-28 | 2019-12-31 | 巴克老龄化研究所 | 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物 |
| KR20220101015A (ko) * | 2014-04-14 | 2022-07-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| US11331328B2 (en) | 2014-05-05 | 2022-05-17 | Bioventures, Llc | Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents |
| CA2955972A1 (en) | 2014-07-22 | 2016-01-28 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2016118855A1 (en) | 2015-01-22 | 2016-07-28 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for selectively depleting senescent cells comprising death receptors |
| WO2016118859A1 (en) | 2015-01-22 | 2016-07-28 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for selectively depleting senescent cells comprising flip |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| KR102616762B1 (ko) * | 2015-03-18 | 2023-12-20 | 아비나스 오퍼레이션스, 인코포레이티드 | 타겟화된 단백질들의 향상된 분해를 위한 화합물들 및 방법들 |
| CN105085620B (zh) | 2015-06-25 | 2018-05-08 | 中山大学附属第一医院 | 一种靶向泛素化降解Smad3的化合物 |
| EP3368025A1 (en) | 2015-07-21 | 2018-09-05 | Fundación Universidad Católica de Valencia San Vicente Mártir | Combination comprising pterostilbene for the treatment of cancer |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US11111259B2 (en) | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| US20190054097A1 (en) | 2016-04-21 | 2019-02-21 | Bioventures, Llc | Compositions targeting senescent cells and the uses thereof |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| ES3041854T3 (en) * | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
-
2017
- 2017-04-21 CN CN201780024822.5A patent/CN109152933B/zh active Active
- 2017-04-21 US US16/095,260 patent/US10807977B2/en active Active
- 2017-04-21 CA CA3018991A patent/CA3018991A1/en active Pending
- 2017-04-21 JP JP2018555177A patent/JP6936498B2/ja active Active
- 2017-04-21 EP EP17786729.8A patent/EP3445452A4/en active Pending
- 2017-04-21 AU AU2017254687A patent/AU2017254687B2/en active Active
- 2017-04-21 WO PCT/US2017/028875 patent/WO2017184995A1/en not_active Ceased
- 2017-04-21 KR KR1020187029999A patent/KR102447884B1/ko active Active
-
2019
- 2019-10-17 WO PCT/US2019/056837 patent/WO2020081880A1/en not_active Ceased
-
2020
- 2020-07-03 US US16/920,649 patent/US11319316B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514877A5 (enExample) | ||
| JP2015518831A5 (enExample) | ||
| RU2016134258A (ru) | Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами | |
| EP4241847C0 (en) | ENHANCED CELL TARGETING BINDING MOLECULE | |
| EP3717505A4 (en) | GENENICALLY MODIFIED DNA-BINDING PROTEINS | |
| CY1118442T1 (el) | Μεθοδοι αγωγης δια της χρησεως εκλεκτικων αναστολεων bcl-2 | |
| JP2014520120A5 (enExample) | ||
| CY1117929T1 (el) | Παραγωγα σουλφοναμιδιου ως bcl-2-εκλεκτικοι παραγοντες διεγερσης αποπτωσης για τη θεραπεια καρκινου και ανοσοασθενειων | |
| EP2124555A4 (en) | NUCLEOSIDARYLPHOSPHORAMIDATE FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS | |
| JP2021502388A5 (enExample) | ||
| EP2560476A4 (en) | COMBINATIONS WITH CRY34AB / 35AB AND CRY3AA PROTEINS TO PREVENT THE DEVELOPMENT OF RESISTANCE IN CORAL ROOT DRILLS (DIABROTICA SPP.) | |
| CY1119134T1 (el) | Υποδοχεις της νεπριλυσινης | |
| JP2013047244A5 (enExample) | ||
| CY1116011T1 (el) | Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανει | |
| EA201370150A1 (ru) | Полиморфные формы 2-(5-бром-4-(4-циклопропилнафталин-1-ил)-4h-1,2,4-триазол-3-илтио)уксусной кислоты и их применение | |
| EA201291009A1 (ru) | Улучшенные связывающие варианты против сывороточного альбумина | |
| EA201000948A1 (ru) | Ингибиторы вирусной полимеразы | |
| EP3917542A4 (en) | MULTISPECIFIC BINDING PROTEINS | |
| CN111601791A (zh) | Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
| EP3708667A4 (en) | IMMUNOGLOBULIN BINDING PROTEINS | |
| JP2010520851A5 (enExample) | ||
| EP3837271A4 (en) | SINGLE MOLECULE SEQUENCING PEPTIDES BOUND TO THE MAIN HISTOCOMPATIBILITY COMPLEX | |
| EP3766972A4 (en) | NUCLEIC ACID COMPLEX | |
| BR112015007879A2 (pt) | inibidores do vírus da hepatite c | |
| JP2011016798A5 (enExample) |